中国循证医学杂志

中国循证医学杂志

中国心房颤动诊疗指南的质量评价

查看全文

目的评价中国心房颤动诊疗指南的方法学质量,为今后制订和更新我国房颤指南提供方法学参考。 方法计算机检索 CBM、CNKI、WanFang Data 和 VIP 数据库,搜集我国发布的心房颤动诊疗指南,检索时限均从建库至 2018 年 2 月。由 2 名研究者独立筛选文献、提取资料后,使用指南质量评价工具 AGREEⅡ对纳入指南进行质量评价。 结果共纳入我国房颤诊疗指南 10 篇。AGREE Ⅱ标化平均得分为:“范围和目的”54.17%、“参与人员”18.89%、“制订的严谨性”15.89%、“表达的清晰性”66.39%、“应用性”34.90%、“编辑独立性”为 0。 结论我国房颤诊疗指南在制订的方法学上存在缺陷,距离循证制订指南有一定差距,未来需在指南制订流程的严谨性和报道规范上进一步强化。

ObjectivesTo assess the methodological quality of Chinese clinical practice guidelines (CPGs) for diagnosis and management of atrial fibrillation, and to provide methodological advice for developing and updating CPGs for atrial fibrillation in future. MethodsCBM, CNKI, WanFang Data and VIP databases were electronically searched to collect filter relevant CPGs from inception to Feburary, 2018. Two reviewers independently screened literature, extracted data and evaluated the quality of eligible CPGs by using the appraisal of guidelines for research and evaluation (AGREE Ⅱ) instrument. ResultsA total of 10 CPGs were included. The standardized mean scores for AGREE Ⅱ were: 54.17% for scope and purpose, 18.89% for stakeholder involvement, 15.89% for rigor of development, 66.39% for clarity and presentation, 34.9% for applicability, and 0 for editorial independence. ConclusionsThe quality of Chinese CPGs for atrial fibrillation is low. More efforts should be made to enhance the quality of CPGs for atrial fibrillation using methodological rigorous frameworks and strengthen guideline reporting.

关键词: 心房颤动; 临床实践指南; 质量评价; AGREE Ⅱ

Key words: Atrial fibrillation; Clinical practice guideline; Quality assessment; AGREE Ⅱ

引用本文: 肖正华, 卢晨, 项蒙蒙, 张煜, 郭新利, 杨鹏, 黄尧, 胡佳. 中国心房颤动诊疗指南的质量评价. 中国循证医学杂志, 2019, 19(2): 199-204. doi: 10.7507/1672-2531.201807083 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the framingham heart study. JAMA, 1994, 271(11): 840.
2. 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究. 中华内科杂志, 2004, 43(7): 491-494.
3. Wang X, Fu Q, Song F, et al. Prevalence of atrial fibrillation in different socioeconomic regions of China and its association with stroke: results from a national stroke screening survey. Int J Cardiol, 2018, 271: 92-97.
4. 梅举, 姜兆磊, 汤敏, 等. 微创心脏瓣膜手术同期双房冷冻消融治疗合并心房颤动. 中国胸心血管外科临床杂志, 2017, 24(1): 25-29.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke, 1991, 22(8): 983.
6. Guo Y, Tian Y, Wang H, et al. Prevalencmne, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest, 2015, 147(1): 109-119.
7. 陈新, 张澍, 胡大一, 等. 心房颤动: 目前认识和治疗建议. 中华心律失常学杂志, 2001, 5(2): 69-94.
8. AGREE Next Steps Consortium. The AGREE Ⅱ instrument, 2009. Available at: http://www.agreetrust.org.
9. Sabharwal S, Patel V, Nijjer SS, et al. Guidelines in cardiac clinical practice: evaluation of their methodological quality using the AGREE Ⅱ instrument. J R Soc Med, 2013, 106(8): 315-322.
10. Galvez-Olortegui JK, Ãlvarez-Vargas ML, Galvez-Olortegui TV, et al. Current clinical practice guidelines in atrial fibrillation: a review. Medwave, 2016, 16(1): 6365.
11. Institute of Medicine (US) Committee to advise the public health service on clinical practice guidelines. Clinical practice guidelines: directions for a new program. Ann Oncol, 1990, 60(9): 343-348.
12. 黄从新, 马长生, 杨延宗, 等. 代表中华医学会心电生理和起搏分会心房颤动治疗专家工作组. 心房颤动: 目前的认识和治疗建议 (二). 中华心律失常学杂志, 2006, 19(3): 167-197.
13. 黄从新, 马长生, 张澍, 等. 经导管消融心房颤动中国专家共识. 中华心律失常学杂志, 2008, 12(4): 248-258.
14. 佚名. 慢性心力衰竭合并心房颤动诊断与治疗中国专家共识. 中国医刊, 2011, 46(1): 78-84.
15. 黄从新, 张澍, 马长生, 等. 心房颤动: 目前的认识和治疗建议-2012. 中国心律失常学杂志, 2012, 16(4): 246-289.
16. 中华医学会心血管病学分会, 心律失常联盟. 心房颤动抗凝治疗中国专家共识. 中华内科杂志, 2012, 51(11): 916-921.
17. 利伐沙班临床应用中国专家组. 利伐沙班临床应用中国专家建议-非瓣膜病心房颤动卒中预防分册. 中华内科杂志, 2013, 52(10): 897-902.
18. 中华医学会心血管病学分会. 非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识. 中华心律失常学杂志, 2014, 18(5): 321-329.
19. 黄从新, 张澍, 黄德嘉, 等. 心房颤动: 目前的认识和治疗建议-2015. 中国心脏起搏与心电生理杂志, 2015, 19(5): 328-369.
20. 张澍, 杨艳敏, 黄从新, 等. 中国心房颤动患者卒中预防规范. 中华心律失常学杂志, 2015, 19(3): 162-173.
21. Graham R, Mancher M. Institute of Medicine (US) Committee on standards for developing trustworthy clinical practice guidelines, clinical practice guidelines we can trust. Washington (DC): National Academies Press (US), 2011.
22. Chen YL, Yao L, Xiao XJ, et al. Quality assessment of clinical guidelines in China: 1993–2010. 中华医学杂志 (英文版), 2012, 125(20): 3660-3664.
23. 韦当, 王小琴, 吴琼芳, 等. 2011 年中国临床实践指南质量评价. 中国循证医学杂志, 2013, 13(6): 760-763.
24. 李楠, 姚亮, 吴琼芳, 等. 2012–2013 年中国大陆期刊发表临床实践指南质量评价. 中国循证医学杂志, 2015, 15(3): 259-263.
25. Álvarez-Vargas ML, Galvez-Olortegui JK, Galvez-Olortegui TV, et al. Clinical practice guidelines in hypertension: a review. Medwave, 2015, 15(9): e6290.
26. Chen Y, Wang C, Shang H, et al. Clinical practice guidelines in China. BMJ, 2018, 360: j5158.
27. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
28. Avaliable at: http://www.gradeworkinggroup.org.
29. Gordon G, Andrew DO, Elie A, et al. GRADE 指南: Ⅰ.导论-GRADE 证据概要表和结果总结表. 中国循证医学杂志, 2011, 11(4): 437-445.
30. Zheng ZH, Cui SQ, Lu XQ, et al. Analysis of the status of Chinese clinical practice guidelines development. Bmc Health Serv Res, 2012, 12(1): 218.
31. Detsky AS. Sources of bias for authors of clinical practice guidelines. CMAJ, 2006, 175(9): 1033, 1035.